Precision antibody (ambis #2229539)
Ended Purchase Order Awarded Last action
- Contract number
- 75N93024P01059
- Awardee
-
A&G Pharmaceutical, Inc. UEI SN6SWFABJXL1
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $15,500
Award facts
- Opportunity
-
- NOINIAID242229539 Solicitation number
- Contract value 100% obligated
- $15,500.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Columbia, MD 21045, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$3,000 | |
| Original award | $18,500 |
About this award
A&G Pharmaceutical, Inc., operating as Precision Antibody, received a $15,500 firm fixed-price purchase order from the National Institute of Allergy and Infectious Diseases (NIAID) on August 27, 2024, for laboratory testing, fusion, and cloning services. The contract, which carries no set-aside designation, is set to be completed by November 30, 2024, and will be performed in Columbia, Maryland. This award represents NIAID's continued investment in specialized biological research materials and custom antibody development capabilities that support the agency's mission to conduct and support research on infectious diseases and immunological conditions.
This purchase order is issued under A&G Pharmaceutical's existing $10 million Blanket Purchase Agreement with the National Institutes of Health Office of Logistics and Acquisition Operations, effective through January 31, 2026. The company has demonstrated sustained success in the federal biomedical research marketplace over two decades, with a consistent track record of awards from NIAID and the National Center for Advancing Translational Sciences for monoclonal and polyclonal antibody production, cell line generation, and laboratory testing services. The BPA framework enables A&G Pharmaceutical to serve as a strategic reagent development partner across multiple NIH components and the U.S. Department of Agriculture's Agricultural Research Service.
Quick answers
Who was awarded contract 75N93024P01059?
75N93024P01059 was awarded to A&G Pharmaceutical, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 27, 2024.
How much is contract 75N93024P01059 worth?
The government has obligated $15,500 on 75N93024P01059.
Was contract 75N93024P01059 competed?
The extent of competition for 75N93024P01059 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award